Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...

Courtesy Staci Rice, Classified as a GLP-1, appetite-suppressing medications, semaglutide is the active ingredient in anti-obesity jabs like Wegovy, and in the anti-diabetes drug Ozempic.

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the press and the medical community for its ability to trigger profound weight loss.

Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...

Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s.

The weight loss drug semaglutide was a "miracle" for Staci Rice. Her cravings and "food noise" disappeared, and it help her lose 64 pounds in around eight months. But, even in its cheaper forms ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...